Results 261 to 270 of about 2,830,257 (398)

Comparative study of greater occipital nerve block and conventional therapy in chronic migraine [PDF]

Kaushal Kabir, Ritu Pauranik, Kanhaiya Agrawal, Manish Banjare   +3 more
openalex   +1 more source

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Using the fear‐avoidance model (FAM) as a theoretical framework, this study examined the interactions between empirical factors contributing to disability in episodic migraine. It was tested whether pain catastrophizing, fear of attacks, and depressiveness mediate the relationship between pain experience and disability.
Janosch Fox, Charly Gaul, Merle Kuhlencord, Nicolina Peperkorn, Julia Ohse, Joshua Krutzki, Youssef Shiban   +6 more
wiley   +1 more source

Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study. [PDF]

J Headache Pain
Scuteri D, Pagliaro M, Iannacchero R, Trimboli M, Lawrence GW, Bagetta G, Corasaniti MT.   +6 more
europepmc   +1 more source

Postpartum Cerebral Angiopathy in a Patient With Chronic Migraine With Aura [PDF]

, 2000
Mala Modi, Girish Modi
openalex   +1 more source

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen, Aaron Jenkins, Karin Hygge Blakeman, Feng Dai, Lucy Abraham, Chelsea Leroue, Josh Brown   +6 more
wiley   +1 more source

Selective loss and transcriptional reprogramming of Nox4⁺ GABAergic neurons in the trigeminal nucleus caudalis of NTG-induced chronic migraine model. [PDF]

J Headache Pain
Xu Y, Deng Y, Wu P, Tian M, Liu C, Liu X, Liu D, Guo Y, Wang P, Xu Y, Wang Y, Li Y.   +11 more
europepmc   +1 more source

The potential role of sleep quality in the relationship between glymphatic function and migraine frequency: Insights from a cross‐sectional study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to explore the association between glymphatic function, as assessed by the diffusion tensor imaging along perivascular space (DTI‐ALPS) index, and headache frequency in individuals with migraine. Additionally, it evaluated whether sleep quality modulates this relationship.
Raffaele Ornello, Federico Salfi, Maria Grazia Vittorini, Antonio Innocenzi, Federico De Santis, Federico Bruno, Francesca Pistoia, Michele Ferrara, Alessandra Splendiani, Simona Sacco   +9 more
wiley   +1 more source

Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies [PDF]

, 2016
Sheena K. Aurora, Mitchell F. Brin
openalex   +1 more source

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Chronic migraine is a debilitating neurological disorder characterized by central sensitization and impaired brainstem habituation. OnabotulinumtoxinA is an established prophylactic treatment for chronic migraine, yet its effects on central trigeminal sensory processing remain incompletely understood.
Gerlinde Freimark, Sebastian Strauss, Lucas H. Overeem, Mira P. Fitzek, Kristin S. Lange, Carolin L. Höhne, Uwe Reuter, Robert Fleischmann, Bianca Raffaelli   +8 more
wiley   +1 more source